Trokendi Xr Capsule, Extended Release
NDC Package 17772-101-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Trokendi Xr (topiramate) capsules is topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This formulation utilizes a capsule, extended release delivery system. Marketed by Supernus Pharmaceuticals, Inc., this product is identified by NDC 17772-101 and is authorized under FDA application NDA201635.

Identification & Billing

NDC Package Code
17772-101-01
Package Description
100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
17772-101
11-Digit Billing Format
17772010101
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 1436239 - topiramate 50 MG 24HR Extended Release Oral Capsule
  • RxCUI: 1436239 - 24 HR topiramate 50 MG Extended Release Oral Capsule
  • RxCUI: 1436239 - topiramate 50 MG 24 HR Extended Release Oral Capsule
  • RxCUI: 1436245 - Trokendi 50 MG 24HR Extended Release Oral Capsule
  • RxCUI: 1436245 - 24 HR topiramate 50 MG Extended Release Oral Capsule [Trokendi]

Clinical Specifications

Proprietary Name
Trokendi Xr
Non-Proprietary Name
Topiramate
Substance Name
Topiramate
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
TOPIRAMATE 25 mg/1
Pharmacologic Class
Usage Information
Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). It is also used to prevent migraine headaches. Topiramate belongs to a class of drugs known as anticonvulsants.

Regulatory & Marketing

Labeler Name
Supernus Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA201635
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-16-2013
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (17772-101). Click a package code to view its specific billing and regulatory data.

17772-101-07
7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
17772-101-10
5 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK
17772-101-12
7 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK
17772-101-15
30 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK
17772-101-30
30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
17772-101-70
7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 17772-101-01 identifies a specific commercial package of 100 capsule, extended release in 1 bottle of Trokendi Xr, a human prescription drug labeled by Supernus Pharmaceuticals, Inc.. This capsule, extended release is formulated for oral use and contains topiramate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Supernus Pharmaceuticals, Inc. on August 16, 2013. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). It is also used to prevent migraine headaches. Topiramate belongs to a class of drugs known as anticonvulsants.

How is this Supernus Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 17772010101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
17772-101-01
11-Digit CMS (5-4-2)
17772-0101-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.